ReviewBioMed research international2016
Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease.
Review in BioMed research international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Pooled it
- Trial
- TRAIL and RIPK3 Do Not Predict Mortality and Acute Kidney Injury in Critically Ill Patients at Admission to the Intensive Care Unit-A Single-Center Cohort Study.International journal of molecular sciences · 2025Article
- Osteoprotegerin as a Potential Biomarker for Breast Cancer: A Study of Its Relationship with Bone Health, vitamin D, and Calcium Levels.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Extra-osseous Roles of the RANK-RANKL-OPG Axis with a Focus on Skeletal Muscle.Current osteoporosis reports · 2024Review
- Osteoprotegerin (OPG): A potential biomarker for adverse cardiovascular events in stable coronary artery disease.Health science reports · 2024Article
- Osteoprotegerin Is Essential for the Development of Endothelial Dysfunction Induced by Angiotensin II in Mice.International journal of molecular sciences · 2024Article
- Preliminary Study on Pulse Wave Changes in Patients with Inflammatory Arthropathies Treated with bDMARDs.Journal of clinical medicine · 2024Article
- Preterm newborns exposed to early-onset preeclampsia have altered postnatal Tumor Necrosis Factor-related apoptosis-inducing ligand trends versus controls.Pediatric research · 2023Article
- Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease.Current obesity reports · 2023Review
- Tumor Necrosis Factor Family Members and Myocardial Ischemia-Reperfusion Injury: State of the Art and Therapeutic Implications.International journal of molecular sciences · 2023Review
- Plasma osteoprotegerin predicts adverse cardiovascular events in stable coronary artery disease: the PEACE trial.Frontiers in cardiovascular medicine · 2023Article
- Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases.Heart failure reviews · 2022Review
- Paradoxical effects of osteoprotegerin on vascular function: inhibiting inflammation while promoting oxidative stress?Clinical science (London, England : 1979) · 2022Article
- Repositioning the Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) on the TRAIL to the Development of Diabetes Mellitus: An Update of Experimental and Clinical Evidence.International journal of molecular sciences · 2022Review
- Roles of osteoprotegerin in endocrine and metabolic disorders through receptor activator of nuclear factor kappa-B ligand/receptor activator of nuclear factor kappa-B signaling.Frontiers in cell and developmental biology · 2022Review
- Noise-augmented directional clustering of genetic association data identifies distinct mechanisms underlying obesity.PLoS genetics · 2022Article
- TRAIL/DR5 pathway promotes AKT phosphorylation, skeletal muscle differentiation, and glucose uptake.Cell death & disease · 2021Article
- Biomarkers of subclinical atherosclerosis in patients with psoriasis.Scientific reports · 2021Article
- TRAIL and Cardiovascular Disease-A Risk Factor or Risk Marker: A Systematic Review.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVD) remain the major cause of death and premature disability in Western societies. Assessing the risk of CVD is an important aspect in clinical decision-making. Among the growing number of molecules that are studied for their potential utility as CVD biomarkers, a lot of attention has been focused on osteoprotegerin (OPG) and its ligands, which are receptor activator of nuclear factor κB ligand (RANKL) and TNF-related apoptosis-inducing ligand. Based on the existing literature and on our experience in this field, here we review what the possible roles of OPG and TRAIL in CVD are and their potential utility as CVD biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.